Glucagon-like peptide-1 receptor agonists (GLP-1-RAs), US Food and Drug Administration-approved for diabetes and weight loss, have recently shown promise in small case studies reporting improved glycemic control and decreased HS severity over short durations.3, 4, 5. Here, GLP1R is linked to diabetes mellitus.